191 related articles for article (PubMed ID: 35175968)
21. Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer.
Su P; Hu J; Zhang H; Jia M; Li W; Jing X; Zhou G
Diagn Pathol; 2014 Jun; 9():119. PubMed ID: 24934762
[TBL] [Abstract][Full Text] [Related]
22. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract][Full Text] [Related]
23. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
24. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
Schwartz CJ; Ruiz J; Bean GR; Sirohi D; Joseph NM; Hosfield EM; Jacobs TW; Mukhtar RA; Chen YY; Krings G
Mod Pathol; 2023 May; 36(5):100125. PubMed ID: 36870308
[TBL] [Abstract][Full Text] [Related]
25. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
26. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
Krings G; Chen YY
Mod Pathol; 2018 Nov; 31(11):1661-1674. PubMed ID: 29946183
[TBL] [Abstract][Full Text] [Related]
27. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast.
Wang J; Wang WL; Sun H; Huo L; Wu Y; Chen H; Gan Q; Meis JM; Maloney N; Lazar AJ; Yoon EC; Albarracin CT; Krishnamurthy S; Middleton LP; Resetkova E; Yu W; Tan D; Lu W; Solis Soto LM; Wang S; Wistuba II; Parwani AV; Prieto VG; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Mar; 121():73-80. PubMed ID: 35063444
[TBL] [Abstract][Full Text] [Related]
28. Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?
Zaborowski M; Gill AJ
Pathology; 2019 Oct; 51(6):653-655. PubMed ID: 31470990
[No Abstract] [Full Text] [Related]
29. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].
Weigelt B; Ng CK; Shen R; Popova T; Schizas M; Natrajan R; Mariani O; Stern MH; Norton L; Vincent-Salomon A; Reis-Filho JS
Mod Pathol; 2015 Mar; 28(3):340-51. PubMed ID: 25412848
[TBL] [Abstract][Full Text] [Related]
30. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
31. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
32. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
33. GATA binding protein 3 (GATA3) as a marker for metaplastic spindle cell carcinoma of the breast.
Jin C; Hacking S; Sajjan S; Kamanda S; Bhuiya T; Nasim M
Pathol Res Pract; 2021 May; 221():153413. PubMed ID: 33770555
[TBL] [Abstract][Full Text] [Related]
34. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
35. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
36. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
37. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
39. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
